# US 2003/0225285 A1 · Method for preparing intermediates useful in synthesis of retroviral protease inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0225285 A1
- Document ID: US20030225285A1
- Status: Published application
- Kind: A1
- Application number: 10/361,005
- Filed: 2003-02-10
- Published: 2003-12-04
- Earliest claimed: 1990-11-19
- Assignees: G.D. Searle & Co.
- Inventors: John S. Ng; Claire A. Przybyla; Richard A. Mueller; Michael L. Vazquez; Daniel P. Getman
- Web page: https://patentgrep.com/patent/US20030225285A1

## CPC

- C07K 5/06191: {containing heteroatoms different from O, S, or N}
- A61K 31/17: having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64)
- A61K 31/195: having an amino group
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/27: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- C04B 35/632: Organic additives
- C07C 213/00: Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C 213/02: by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
- C07C 213/08: by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
- C07C 269/06: by reactions not involving the formation of carbamate groups
- C07C 271/20: to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
- C07C 271/22: to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
- C07C 275/14: being further substituted by nitrogen atoms not being part of nitro or nitroso groups
- C07C 275/18: of a saturated carbon skeleton containing rings
- C07C 275/22: containing rings other than six-membered aromatic rings
- C07C 275/24: containing six-membered aromatic rings
- C07C 275/28: having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C 311/47: Y being a hetero atom
- C07C 317/44: having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C 317/50: at least one of the nitrogen atoms being part of any of the groups [IMAGE cpc-sch-C07C-0976.gif], X being a hetero atom, Y being any atom
- C07C 323/60: with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
- C07C 329/06: having sulfur atoms of thiocarbonic groups bound to acyclic carbon atoms
- C07C 335/08: of a saturated carbon skeleton
- C07C 335/12: the carbon skeleton containing six-membered aromatic rings
- C07D 213/81: Amides; Imides
- C07D 215/48: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 215/50: attached in position 4
- C07D 215/54: attached in position 3
- C07D 217/26: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 235/06: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D 235/24: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D 239/38: One sulfur atom
- C07D 241/44: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D 295/13: to an acyclic saturated chain
- C07D 295/15: to an acyclic saturated chain
- C07D 303/36: with hydrocarbon radicals, substituted by nitrogen atoms (nitro, nitroso radicals C07D303/08)
- C07D 307/85: attached in position 2
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07K 5/0207: {containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids}
- C07K 5/021: {containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds}
- C07K 5/06026: {the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala}
- C07K 5/06139: {with the first amino acid being heterocyclic}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07B 2200/07: Optical isomers
- C07C 2601/02: with a three-membered ring
- C07C 2601/04: with a four-membered ring
- C07C 2601/08: the ring being saturated
- C07C 2601/14: The ring being saturated
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C04B: LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE {(roofing granules E04D7/005)}; CERAMICS (devitrified glass-ceramics C03C10/00); REFRACTORIES; TREATMENT OF NATURAL STONE
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

A synthesis is described for intermediates which are readily amenable to the large scale preparation of hydroxyethylurea-based chiral HIV protease inhibitors. The method includes forming a diastereoselective epoxide from a chiral alpha amino aldehyde.

## Claims

### Claim 1

A method of preparing an aminoepoxide compound of Formula I:
9
wherein P1 and P2 independently are selected from acyl, aralkyl, alkenyl, silyl, aralkoxycarbonyl, alkoxycarbonyl and cycloalkenylalkyl;
wherein further P1 and P2 may be taken together with the nitrogen atom of Formula I to form a heterocyclic ring system containing said nitrogen atom as a ring member;
and wherein R1 is selected from alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl, which are optionally substituted with a group selected from alkyl, halo, NO2, OR9 and SR9, wherein R9 is selected from hydrogen and alkyl;
and wherein any of the foregoing groups of P1, P2 and R1 may be substituted at one or more substitutable positions with one or more radicals independently selected from halo, alkyl of C1-C8, alkoxy, hydroxy, nitro, alkenyl, amino, alkylamino, acylamino and acyl; or a pharmaceutically-acceptable salt thereof;
said method comprising the steps of forming a protected aminoalcohol, oxidizing said protected aminoalcohol to a chiral protected aminoaldehyde and diastereoselectively forming the aminoepoxide from said aminoaldehyde with an organometallic methylene-adding reagent in an appropriate solvent.

### Claim 2 (depends on 1)

The method of claim 1 wherein P1 and P2 independently are selected from carbobenzoxy, t-butoxycarbonyl, acetyl, butyryl, benzoyl, isobutyloxycarbonyl, allyl, 1,2-bis(dimethylsilyl)ethane, 1,2-bis(dimethylsilyl)benzene, substituted benzoyl, trifluoroacetyl, trichloroacetyl, phthaloyl, benzyl, ortho-methylbenzyl, trityl, 1,2-bis(methylene)benzene, benzhydryl, phenethyl, phenpropyl, phenyl, naphthalenyl, indenyl, anthracenyl, durenyl, 9-(9-phenyl-fluoroenyl) and phenanthrenyl, wherein further P1 and P2 may be taken together to form with the nitrogen atom of Formula I a radical selected from phthalimide, succinimide and maleimide, and wherein any of the foregoing groups of P1 and P2 may be substituted at one or more substitutable positions with one or more radicals independently selected from halo, alkyl of C1-C8, alkoxy, hydroxy, nitro, alkenyl, amino, alkylamino, acylamino and acyl; or a pharmaceutically-acceptable salt thereof.

### Claim 3 (depends on 1)

The method of claim 1 wherein P1 and P2 are independently selected from aralkyl, 1-2-bis(methylene)benzene and aralkyl substituted with one or more radicals independently selected from halo, alkyl of C1-C8, alkoxy, hydroxy, nitro, alkenyl, amino, alkylamino, acylamino and acyl; and wherein R1 is aralkyl; or a pharmaceutically-acceptable salt thereof.

### Claim 4

A diastereoselective and enantioselective method of preparing a protected chiral alpha-amino epoxide of Formula I:
10
wherein P1 and P2 independently are selected from acyl, aralkyl, alkenyl, silyl, aralkoxycarbonyl, alkoxycarbonyl and cycloalkenylalkyl;
wherein further P1 and P2 may be taken together with the nitrogen atom of Formula I to form a heterocyclic ring system containing said nitrogen atom as a ring member;
and wherein R1 is selected from alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl, which are optionally substituted with a group selected from alkyl, halo, NO2, OR9 and SR9, wherein R9 is selected from hydrogen and alkyl;
and wherein any of the foregoing groups of P1, P2 and R1 may be substituted at one or more substitutable positions with one or more radicals independently selected from halo, alkyl of C1-C8, alkoxy, hydroxy, nitro, alkenyl, amino, alkylamino, acylamino and acyl; or a pharmaceutically-acceptable salt thereof;
said method comprising treating a protected aminoaldehyde substrate with an organometallic methylene-adding reagent in an appropriate solvent.

### Claim 5 (depends on 4)

The method of claim 4 wherein the organometallic methylene-adding reagent is a halomethyllithium generated in situ.

### Claim 6 (depends on 5)

The method of claim 5 wherein at least an equimolar amount of organometallic methylene-adding reagent is added to the aminoaldehyde.

### Claim 7 (depends on 4)

The method of claim 4 wherein the halomethyllithium is formed through the addition of an organolithium reagent with a dihalomethane.

### Claim 8 (depends on 4)

The method of claim 4 wherein the dihalomethane is selected from bromochloromethane, chloroiodomethane, dibromomethane, diiodomethane and bromofluoromethane.

### Claim 9 (depends on 4)

The method of claim 4 wherein the halomethyllithium is added to the amino aldehyde at a temperature in a range of about −80° C. to about 0° C.

### Claim 10 (depends on 4)

The method of claim 4 wherein the halomethyllithium is added to the amino aldehyde at a temperature in a range of about −40° C. and −15° C.

### Claim 11 (depends on 4)

The diastereoselective method of preparing protected chiral alpha-amino epoxides of claim 4 wherein the amino aldehyde is alpha-S-[bis(phenylmethyl)amino]-benzenepropanaldehyde.

### Claim 12

A method of forming protected alpha-aminoaldehyde of Formula III:
11
wherein P1 and P2 independently are selected from acyl, aralkyl, alkenyl, silyl, aralkoxycarbonyl, alkoxycarbonyl and cycloalkenylalkyl;
wherein further P1 and P2 may be taken together with the nitrogen atom of Formula III to form a heterocyclic ring system containing said nitrogen atom as a ring member;
and wherein R1 is selected from alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl, which are optionally substituted with a group selected from alkyl, halo, NO2, OR9 and SR9, wherein R9 is selected from hydrogen and alkyl;
and wherein any of the foregoing groups of P1, P2 and R1 may be substituted at one or more substitutable positions with one or more radicals independently selected from halo, alkyl of C1-C8, alkoxy, hydroxy, nitro, alkenyl, amino, alkylamino, acylamino and acyl; or a pharmaceutically-acceptable salt thereof;
said method comprising treating at a temperature of about 0° C. to about 30° C. a protected aminoalcohol with an oxidizing agent.

### Claim 13 (depends on 12)

The method of claim 12 wherein at least an equimolar amount of said oxidizing agent is added to the protected aminoalcohol.

### Claim 14 (depends on 12)

The method of claim 12 wherein said oxidizing agent is selected from sulfur trioxide:pyridine complex, acetyl chloride/dimethyl sulfoxide, acetyl anhydride/dimethyl sulfoxide, trifluoroacetyl chloride/dimethyl sulfoxide, toluenesulfonyl bromide/dimethyl sulfoxide, phosphorous pentachloride/dimethyl sulfoxide and isobutylchlorformate/dimethyl sulfoxide.

### Claim 15 (depends on 12)

The method of claim 12 wherein said oxidizing agent is sulfur trioxide:pyridine complex in an appropriate solvent.

### Claim 16 (depends on 12)

The method of claim 12 wherein the reaction temperature is between about 15° C. and about 30° C.

### Claim 17 (depends on 12)

The method of claim 12 wherein the protected aminoalcohol is [Bis(phenylmethyl)amino)-benzenepropanol.

### Claim 18

A method of preparing protected chiral alpha-amino alcohol of the formula:
12
wherein P1 and P2 independently are selected from acyl, aralkyl, alkenyl, silyl, aralkoxycarbonyl, alkoxycarbonyl and cycloalkenylalkyl;
wherein further P1 and P2 may be taken together with the nitrogen atom of Formula II to form a heterocyclic ring system containing said nitrogen atom as a ring member;
and wherein R1 is selected From alkyl, aryl, cycloalkyl, cycloalkylalkyl and arylalkyl, which are optionally substituted at one or more substitutable positions with a group selected from alkyl, halo, NO2, OR9 and SR9, wherein R9 is selected from hydrogen and alkyl;
and wherein any of the foregoing groups of P1, P2 and R1 may be substituted with one or more radicals independently selected from halo, alkyl of C1-C3, alkoxy, hydroxy, nitro, alkenyl, amino, alkylamino, acylamino and acyl; or a pharmaceutically-acceptable salt thereof;
said method comprising treating said aminoalcohol with an alkylazing agent.

### Claim 19 (depends on 18)

The method of claim 18 wherein the aminoalcohol is L-phenylalaninol

### Claim 20 (depends on 1)

A method according to claim 1 characterized in that the protected chiral alpha-amino alcohol of Formula II:
13
as used
wherein P1, P2 and R1 are defined as indicated in claim 1 is formed by treating an amino acid with an alkylating agent to form a protected-amino acid, and forming a protected amino-alcohol by treating said protected amino acid with a reducing agent in a suitable solvent.

### Claim 21 (depends on 20)

The method of claim 20 wherein the reducing agent is diisobutylaluminum hydride.

### Claim 22 (depends on 20)

The method of claim 20 wherein said amino acid is L-phenylalanine.
